TABLE 2.
Antiviral activities of siRNAs in combination with cidofovir in A549 cellsa
siRNA | Virus titer reduction (log10 TCID50/ml)b
|
Enhancement of cidofovir activitvc (log10 TCID50/ml) | Synergistic interactiond (log10 TCID50/ml) | |
---|---|---|---|---|
siRNA alone | siRNA in combination with cidofovir | |||
siB1R-2 | 0.5 | 1.1 | +0.6 | +0.1 |
siG7L-1 | 1.2 | 2.8 | +2.3 | +1.1 |
siD5R-2 | 1.2 | 3.0 | +2.5 | +1.3 |
0.5 |
Cells were transfected with the siRNA of interest (siD5R-2, siB1R-2, or siG7L-1) at a concentration of 1 nM. At 24 hours posttransfection, cells were infected with VACV-WR at an MOI of 0.0001 and then treated or not with cidofovir (32 μM). Samples were harvested at 48 h postinfection, and viral titers (log10 50% tissue culture infective dose [TCID50]/ml) were determined in cell culture.
Means of triplicate experiments.
Enhancement of cidofovir activity was calculated with the following formula: enhancement of cidofovir activity = (virus titer with combination of cidofovir and siRNA) − (virus titer with cidofovir alone).
The synergistic effect of the combination was calculated with the following formula: synergistic interaction = (viral titer with combination of cidofovir and siRNA) − (titer with siRNA alone + titer with cidofovir alone).